AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9591766
Drug: Patients on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on therapy (n=13)
Trial: 7611750
Drug: Arm A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: 250 mg/m2 of l‐leucovorin and 600 mg/m2 of 5‐fluorouracil weekly
Trial: 2361638
Drug: Metronidazole tablets
RxNorm normalized name: Metronidazole Tablets
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole tablets 500 mg 3 times daily for 10 days
Trial: 2361638
Drug: Metronidazole (repeated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (repeated treatments, once or twice)
Trial: 58199
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and D.H.E.
Trial: 58199
Drug: Heparin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin alone and Heparin and D.H.E.
Trial: 26053679
Drug: Single-dose antihelminthic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose antihelminthic treatment with 400 mg albendazole
Trial: 10710871
Drug: 0.3% Ofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% Ofloxacin otic solution (OFLX) 6 drops twice daily
Trial: 10710871
Drug: Oral Amoxycillin
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Amoxycillin 500 mg three times daily plus 1% Chloramphenicol ear drop at 3 drops three times daily (AMOX + CRP)
Trial: 24664858
Drug: Caffeinated energy
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated energy drink (3 mg of caffeine per kg of body mass)
Trial: 20671225
Drug: Fluvastatin combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin combined with benazepril-valsartan therapy
Trial: 20671225
Drug: Benazepril-valsartan therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril-valsartan therapy alone
Trial: 19810298
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate powder, equivalent to 20 mg elemental zinc
Trial: 12476650
Drug: Paclitaxel-coated stent
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-coated stent (drug-eluting stent)
Trial: 12476650
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-drug-eluting stent)
Trial: 2360387
Drug: Lidocaine as
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine as laryngotracheal spray (1 mg/kg BW)
Trial: 2360387
Drug: Lidocaine as
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine as transtracheal injection (1 mg/kg BW)
Trial: 2360387
Drug: Lidocaine as
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine as intravenous injection (1 mg/kg BW)
Trial: 118805
Drug: Hexamethylmelamine (HMM)
RxNorm normalized name: HMM
DrugBank: Altretamine (DB00488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hexamethylmelamine (HMM) alone, 300 mg/m2/day x 14 days every 21 days
Trial: 118805
Drug: HOM regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOM regimen (HMM 200 mg/m2/day x 21 days, vincristine 1.5 mg on Days 1, 8, and 15, mitomycin C 12 mg/m2 once every 6 weeks)
Trial: 18050183
Drug: Etanercept treatment
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept treatment in group A (G/A genotype)
Trial: 18050183
Drug: Etanercept treatment
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept treatment in group G (G/G genotype)
Trial: 9475818
Drug: Dolasetron mesylate
RxNorm normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dolasetron mesylate 100 mg
Trial: 20100992
Drug: Norepinephrine increase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine increase during phentolamine infusion
Trial: 30859184
Drug: Nitrofurantoin 100
RxNorm normalized name: nitrofurantoin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin 100 mg q8h
Trial: 3133709
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing regimens
Trial: 21324590
Drug: CST plus
RxNorm normalized name: dimethiconol (50000 CST)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CST plus sertraline
Trial: 14527527
Drug: Sertraline alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline alone
Trial: 17299655
Drug: Perioperative improvements
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative improvements including thorough preoperative haematological checks, administration of inhibitors of fibrinolysis (aprotinin, ε‐aminocaproic acid), minimization of extracorporeal circulation (ECC), and postoperative recovery measures (i.v. iron and recombinant human erythropoietin).
Trial: 11721504
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard therapy: intra-nasal corticosteroids)
Trial: 25376670
Drug: Tri-length laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-length laser therapy (iLux-Triax) and tecar therapy (Pharon), treated three times a week for a total of 10 sessions.
Trial: 25376670
Drug: Tri-length laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri-length laser therapy (iLux-Triax) and tecar therapy (Pharon) in patients with low-back pain and leg pain.
Trial: 16926581
Drug: Interdisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interdisciplinary treatment consisting of education, exercise and stretch, goal setting, medication management, and cognitive and behavioral techniques.
Trial: 9018388
Drug: Paroxetine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine and Fluoxetine (SSRIs)
Trial: 8276043
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg taken once daily with breakfast
Trial: 8276043
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg taken once daily with evening meal
Trial: 31749238
Drug: Bexagliflozin 20
RxNorm normalized name: bexagliflozin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexagliflozin 20 mg
Trial: 25078372
Drug: scFOS-supplemented formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scFOS-supplemented formula (4 g/L scFOS)
Trial: 25078372
Drug: placebo-supplemented formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo-supplemented formula (4 g/L maltodextrins)
Trial: 12736485
Drug: hANP (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hANP (25 microg intracoronary injection + 0.025 microg x kg(‐1) x min(‐1) intravenous infusion for 1 week)
Trial: 11705173
Drug: 0.3 ml
RxNorm normalized name: ethanol 0.3 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 ml low‐molecular weight heparin (Group 2)
Trial: 11705173
Drug: Compression stockings
RxNorm normalized name: Truform Medical Compression Stockings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression stockings and 0.3 ml LMWH (Group 3)
Trial: 9140691
Drug: Amlodipine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 20 mg iv (two doses of 10 mg each)
Trial: 9140691
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 ml, two doses)
Trial: 24506965
Drug: Low-dose carvedilol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose carvedilol combined with candesartan
Trial: 16652033
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of abacavir/lamivudine (FDC)
Trial: 16652033
Drug: Separate entities
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate entities (abacavir twice daily and lamivudine once daily) (SE)
Trial: 12814254
Drug: Combined chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined chemotherapy (vincristine, lomustine, and prednisone or '8-in-1') with involved-field irradiation
Trial: 11009150
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose anthelminthic (400 mg albendazole)
Trial: 11009150
Drug: Daily iron‐folate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron‐folate supplements (36 g iron and 5 mg folate)
Trial: 22435991
Drug: ICG-augmented diode
RxNorm normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG-augmented diode laser treatment (ICG+DL)
Trial: 17217359
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of 400 microgram oral misoprostol
Trial: 17217359
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 400 microgram oral misoprostol
Trial: 8575118
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg and 40 mg
Trial: 16494640
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 2.5 mg
Trial: 2213283
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors or calcium channel blockers
Trial: 31584783
Drug: Kamedis Eczema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kamedis Eczema Therapy Cream (test product)
Trial: 31584783
Drug: Vehicle (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (identical test product without botanical combination)
Trial: 28566590
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg/day for men, 15 mg/day for women)
Trial: 28566590
Drug: Metformin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (750 mg/day)
Trial: 24105252
Drug: Bepotastine besilate
RxNorm normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bepotastine besilate 10 mg (reference)
Trial: 24105252
Drug: Bepotastine salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepotastine salicylate 9.64 mg (test)
Trial: 8326293
Drug: Pravastatin (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (0, 10, 20 and 40 mg day‐1 for 6 weeks)
Trial: 8326293
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (Simvastatin and Pravastatin)
Trial: 3732227
Drug: CO measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO measurement demonstration at the beginning of treatment
Trial: 3732227
Drug: CO measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO measurement demonstration at the end of treatment (prior to self-reports)
Trial: 3732227
Drug: CO measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO measurement demonstration at the end of treatment (subsequent to self-reports)
Trial: 8772902
Drug: Isoniazid 10
RxNorm normalized name: isoniazid 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid 10 mg/kg
Trial: 31910916
Drug: Problem Adaptation
RxNorm normalized name: Psoriasin Problem Skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem Adaptation Therapy (PATH)
Trial: 28223082
Drug: Supportive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Therapy of Cognitively Impaired Older Adults (ST‐CI)
Trial: 10858844
Drug: S‐(+)‐ketamine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐(+)‐ketamine (1.5 mg/kg)
Trial: 10858844
Drug: ketamine‐racemic mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine‐racemic mixture (3 mg/kg)
Trial: 9350068
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of n‐3 PUFA
Trial: 9350068
Drug: 0.65 g
RxNorm normalized name: Tumil-K 2 MEQ/0.65 GM Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.65 g of n‐3 PUFA
Trial: 29588127
Drug: Opioid drugs
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid drugs
Trial: 25912040
Drug: Experimental soy-based
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental soy-based formula 2 (EF2) containing scFOS (2.5 g/L) and mixed carotenoids
Trial: 17923208
Drug: 0.1% mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% mometasone furoate topical cream
Trial: 17923208
Drug: Moisturizing cream
RxNorm normalized name: MOISTURIZING CREAM
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizing cream (placebo)
Trial: 28671857
Drug: Escalating dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dose MTX with PEG asparaginase without leucovorin rescue
Trial: 25981348
Drug: Oral aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral aripiprazole 5mg/day
Trial: 25981348
Drug: Oral aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral aripiprazole 10mg/day
Trial: 25981348
Drug: Oral aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral aripiprazole 20mg/day
Trial: 19216014
Drug: Focused atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused atorvastatin therapy
Trial: 17926823
Drug: Rituximab +
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab + Steroid
Trial: 14716774
Drug: IFN-alpha-intermittent group
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha-intermittent group (3 MU of IFN-alpha daily for 10 days every month for 6 months, then 3 MU daily for 10 days every 3 months for 18 months)
Trial: 14716774
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IFN-alpha therapy)
Trial: 9218075
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.d. plus amoxycillin 750 mg b.d.
Trial: 9218075
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg b.d. plus amoxycillin 750 mg b.d.
Trial: 30926400
Drug: ReHand tablet
RxNorm normalized name: Artemisia Rehan Flowering Top
DrugBank: Wormwood (DB14291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReHand tablet application (experimental group)
Trial: 18300265
Drug: Double-blind placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind placebo (normal saline) with the same dose and frequency (Arm B)
Trial: 15633323
Drug: Injection anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection anesthesia (lidocaine 2% adrenaline)
Trial: 15633323
Drug: Injection anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection anesthesia
Trial: 11734708
Drug: Oral cefixime
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cefixime for 3 days
Trial: 11734708
Drug: Topical polymyxin‐bacitracin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical polymyxin‐bacitracin for 7 days
Trial: 11734708
Drug: Topical polymyxin‐bacitracin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical polymyxin‐bacitracin
Trial: 9222674
Drug: No submucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No submucosal saline injection
Trial: 21545527
Drug: Moderate exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate exercise program (endurance and activity of daily living training, twice a day)
Trial: 3117400
Drug: Adriamycin (ADM)
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin (ADM) group, intravesical instillation with 50 mg ADM dissolved in 100 ml physiological saline; administered six times within 2 weeks, then every 4 weeks for 2 years.
Trial: 3117400
Drug: Control group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group, transurethral resection or transurethral coagulation alone; no drug intervention.
Trial: 31609926
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate capsules at a dose of 90 mg (high-dose) daily for 16 weeks
Trial: 23392882
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2.0 g TAU and 3.2 g BCAA, thrice a day, for 2 weeks prior to and 4 days after exercise
Trial: 23392882
Drug: TAU alone
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU alone (2.0 g)
Trial: 11137327
Drug: Transdermal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal hormone replacement therapy with E2 (50 microg/day) and NETA (170 microg/day)
Trial: 11137327
Drug: Transdermal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal hormone replacement therapy with higher dose of NETA (350 microg/day)
Trial: 8959465
Drug: Minaprine (antidepressant)
RxNorm normalized name: minaprine
DrugBank: Minaprine (DB00805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minaprine (antidepressant)
Trial: 8959465
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo or other antidepressants not specified)
Trial: 30574790
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose enoxaparin (0.8 mg/kg)
Trial: 30194765
Drug: Subtherapeutic levels
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subtherapeutic levels of hypoglossal nerve stimulation therapy (HGNS)
Trial: 18281656
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg PO bid
Trial: 18281656
Drug: Zileuton 600
RxNorm normalized name: zileuton 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton 600 mg PO qid
Trial: 18281656
Drug: Celecoxib and
RxNorm normalized name: amlodipine and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib and Zileuton at the same doses
Trial: 12676601
Drug: Combustion particles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combustion particles (1.0 mg/m3) followed by allergen challenge
Trial: 12676601
Drug: Combustion particles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combustion particles (1.0 mg/m3)
Trial: 3008313
Drug: i.v. applicable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. applicable CMV-hyperimmunoglobulin administered prior to transplant
Trial: 25239590
Drug: Prucalopride (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride (0.04 mg/kg oral solution for children ≤ 50 kg; 2 mg tablet for children > 50 kg) once daily for 8 weeks
Trial: 11669594
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: continuous circadian intra-arterial infusion of 1400 mg/m² 5-FU plus 60 mg/m² i.v. leucovorin and 80 µg/m² GM-CSF (day 1+2) combined with chemoembolization with 25 mg/m² melphalan plus Lipiodol and Gelfoam (day 3)
Trial: 9209730
Drug: Clozapine serum
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine serum level 50-150 ng/mL
Trial: 9209730
Drug: Clozapine serum
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine serum level 200-300 ng/mL
Trial: 9209730
Drug: Clozapine serum
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine serum level 350-450 ng/mL
Trial: 9209730
Drug: Clozapine treatment
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine treatment (general)
Trial: 2142921
Drug: Intranasal buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal buserelin (500 micrograms thrice daily for 10 days, then intranasal)
Trial: 2142921
Drug: Subcutaneous goserelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous goserelin
Trial: 25078981
Drug: Retinaldehyde-based cream
RxNorm normalized name: retinaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinaldehyde-based cream (RA-cream) applied once daily for 3 months